Study guide
15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management
Key Takeaways Explain This Topic AI
Acute symptomatic hyponatremia manifested by seizures or coma requires urgent administration of 3% Hypertonic Saline at 3–5 mL/kg IV over 10–20 minutes, aimed at rapidly raising serum sodium by 3–5 mEq/L to reduce brain swelling.
To prevent osmotic demyelination syndrome (ODS), total chronic hyponatremia correction must not exceed 8–10 mEq/L in 24 hours, with high-risk patients capped at 6–8 mEq/L in 24 hours.
Hypernatremia carries extreme risk of cerebral edema and herniation if corrected rapidly; free water deficits must be replenished slowly over 48 hours with a target rate of serum sodium reduction not exceeding 0.5 mEq/L/hour (max 10–12 mEq/L/day).
Emergency hyperkalemia pharmacotherapy follows a mandatory 3-step hierarchy: immediate cardiac membrane stabilization with calcium gluconate (100 mg/kg IV) or calcium chloride (20 mg/kg centrally); intracellular shifting with regular insulin (0.1 units/kg) plus dextrose (0.5–1 g/kg), nebulized albuterol, and sodium bicarbonate; followed by total-body potassium elimination.
Calcium chloride provides three times more elemental calcium than calcium gluconate (27.2 mg vs 9.3 mg elemental Ca per mL of 10% solution) and must be infused strictly through a central line to prevent catastrophic tissue necrosis.
Last updated: September 2026
15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management
Electrolyte disturbances in pediatric patients represent acute medical emergencies requiring nuanced understanding of cellular physiology, fluid compartments, and pharmacotherapy. Rapid shifts in serum osmolality and transmembrane electrical gradients directly threaten central nervous system and cardiac integrity. Clinical pharmacists must master the differential diagnosis of volume status, calculate exact deficit kinetics, and implement tiered emergency pharmacologic protocols for life-threatening dysnatremias, hyperkalemia, and calcium imbalances.
Sodium Disturbances: Hyponatremia
Hyponatremia is defined as a serum sodium concentration < 135 mEq/L < 135\text{ mEq/L} < 135 mEq/L , with severe hyponatremia defined as < 120 to 125 mEq/L < 120\text{ to } 125\text{ mEq/L} < 120 to 125 mEq/L . True hypotonic hyponatremia decreases extracellular fluid osmolality, establishing a transcellular osmotic gradient that drives water into brain cells, causing acute cerebral edema , raised intracranial pressure, uncal herniation, and death. Because pediatric brains have a higher brain-to-cranial vault volume ratio and immature N a + / K + Na^+/K^+ N a + / K + ATPase extrusion pumps, children are at substantially higher risk of cerebral herniation than adults at identical serum sodium levels.
Diagnostic Classification by Volume Status Diagnostic Algorithm for Pediatric Hypotonic Hyponatremia (Serum Osm < 280 mOsm/kg):
- [Assess Extracellular Volume Status]
- │
- ┌──────────────────────────────────────┼──────────────────────────────────────┐
- ▼ ▼ ▼
- [HYPOVOLEMIC HYPONATREMIA] [EUVOLEMIC HYPONATREMIA] [HYPERVOLEMIC HYPONATREMIA]
- (Dry mucosa, tachycardia, (Normal turgor, no edema, (Peripheral edema, ascites,
- orthostasis, flat veins) normal blood pressure) pulmonary rales, S3 gallop)
- │ │ │
- Check Urine Sodium Check Urine Sodium Check Urine Sodium
- ┌──────┴──────┐ ┌──────┴──────┐ ┌──────┴──────┐
- ▼ ▼ ▼ ▼ ▼ ▼
- < 20 mEq/L > 20 mEq/L > 20-40 mEq/L < 20 mEq/L < 20 mEq/L > 20 mEq/L
- Extrarenal Renal Loss • SIADH Water intoxication • CHF Acute/Chronic
- Losses • Diuretics • CNS/Lung (Formula dilution) • Nephrotic Renal Failure
- Diarrhea • Cerebral Salt Wasting infection • Cirrhosis
- Vomiting • Adrenal Crisis (CAH) • Carbamazepine
Hypovolemic Hyponatremia: Total body sodium deficit exceeds water deficit.
Etiology: Gastrointestinal losses (diarrhea, vomiting), burns, third-spacing, adrenal insufficiency (congenital adrenal hyperplasia [CAH] with 21-hydroxylase deficiency), or Cerebral Salt Wasting (CSW) seen after neurosurgery or traumatic brain injury.
Laboratory Profile: Low urine sodium ( < 20 mEq/L < 20\text{ mEq/L} < 20 mEq/L ) in extrarenal losses; elevated urine sodium ( > 20 to 40 mEq/L > 20\text{ to } 40\text{ mEq/L} > 20 to 40 mEq/L ) in renal salt wasting, diuretic therapy, or CSW.
Treatment: Volume restoration with isotonic crystalloids ( 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl ). CSW requires vigorous volume and sodium replacement, often with oral salt supplementation or fludrocortisone.
Euvolemic Hyponatremia: Normal total body sodium with expanded total body water.
Etiology: Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is the primary cause. Secondary to CNS disorders (meningitis, encephalitis, intracranial hemorrhage, tumors), pulmonary pathologies (pneumonia, bronchiolitis, mechanical ventilation), post-operative stress, and medications ( carbamazepine, oxcarbazepine, vincristine, cyclophosphamide, SSRIs ).
Diagnostic Hallmarks of SIADH: Serum hypoosmolality ( < 275 mOsm/kg < 275\text{ mOsm/kg} < 275 mOsm/kg ), concentrated urine (urine osmolality > 100 – 300 mOsm/kg > 100\text{--}300\text{ mOsm/kg} > 100 – 300 mOsm/kg , almost always exceeding serum osmolality), elevated urine sodium ( > 20 to 40 mEq/L > 20\text{ to } 40\text{ mEq/L} > 20 to 40 mEq/L ) despite normal dietary salt intake, clinical euvolemia, and normal adrenal/thyroid function.
Treatment: Fluid restriction to 50 % to 75 % 50\%\text{ to } 75\% 50% to 75% of maintenance is the first-line therapy. In refractory cases, oral urea or loop diuretics with oral sodium chloride tablets may be added. Vasopressin receptor antagonists (vaptans) are rarely used in pediatrics due to unpredictably rapid overcorrection risks.
Hypervolemic Hyponatremia: Total body water expansion exceeds total body sodium expansion.
Etiology: Congestive heart failure, nephrotic syndrome, acute/chronic renal failure, and hepatic cirrhosis.
Laboratory Profile: Urine sodium < 20 mEq/L < 20\text{ mEq/L} < 20 mEq/L (reflecting poor effective arterial blood volume) unless renal failure is the primary cause.
Treatment: Sodium and fluid restriction combined with loop diuretics (furosemide 1 to 2 mg/kg 1\text{ to } 2\text{ mg/kg} 1 to 2 mg/kg IV).
Acute Symptomatic Hyponatremia: Emergency Management
When hyponatremia is complicated by neurological emergencies—such as generalized tonic-clonic seizures, altered mental status, stupor, or signs of impending brainstem herniation —clinicians must intervene immediately without waiting for diagnostic workups.
Pharmacologic Agent: 3 % Hypertonic Saline 3\%\text{ Hypertonic Saline} 3% Hypertonic Saline ( 513 mEq/L N a + 513\text{ mEq/L } Na^+ 513 mEq/L N a + and C l − Cl^- C l − , or ∼ 0.5 mEq/mL \sim 0.5\text{ mEq/mL} ∼ 0.5 mEq/mL ) .
Dose: 3 to 5 mL/kg 3\text{ to } 5\text{ mL/kg} 3 to 5 mL/kg IV infused over 10 to 20 minutes (maximum single bolus 100 to 150 mL 100\text{ to } 150\text{ mL} 100 to 150 mL ).
Repetition: If active seizures or coma persist, the 3 to 5 mL/kg 3\text{ to } 5\text{ mL/kg} 3 to 5 mL/kg bolus may be repeated once or twice until seizure cessation.
Target Response: The goal of acute hypertonic saline is not to normalize serum sodium, but to raise the serum sodium by 3 to 5 mEq/L 3\text{ to } 5\text{ mEq/L} 3 to 5 mEq/L . This small acute elevation expands extracellular osmolality sufficiently to decrease brain water content by 5 % to 10 % 5\%\text{ to } 10\% 5% to 10% , rapidly halting cerebral herniation and terminating seizures.
The 24-Hour Correction Ceiling: Preventing Osmotic Demyelination Syndrome Transcellular Osmotic Dynamics in Hyponatremia Correction:
- [Chronic Hyponatremic State] ───( Rapid Hypertonic Overcorrection )───► [Dehydration of Brain Cells]
- Brain cells lost organic osmoles Oligodendrocytes shrink rapidly;
- (taurine, myo-inositol) to adapt myelin sheaths detach from axons
- to low extracellular tonicity. │
- ▼
- OSMOTIC DEMYELINATION
- SYNDROME (ODS / CPM)
- Spastic quadriparesis
- Pseudobulbar palsy
- "Locked-in" syndrome
Caution
Osmotic Demyelination Syndrome (ODS): In chronic hyponatremia ( > 48 hours > 48\text{ hours} > 48 hours duration), astrocytes extrude organic intracellular osmoles (myo-inositol, taurine, glutamate) to defend cell volume. If serum sodium is corrected too rapidly, the extracellular space becomes acutely hypertonic relative to the depleted brain cells. Water rapidly leaves brain cells, causing dehydration of oligodendrocytes, detachment of myelin sheaths, and catastrophic osmotic demyelination syndrome (formerly central pontine myelinolysis). Symptoms manifest 2 to 6 days post-correction as dysarthria, dysphagia, spastic quadriparesis, encephalopathy, and permanent "locked-in" syndrome.
Maximum 24-Hour Correction Ceiling: Total serum sodium increase must NOT exceed 8 to 10 mEq/L 8\text{ to } 10\text{ mEq/L} 8 to 10 mEq/L in any 24-hour period (or ≤ 0.5 mEq/L/hour \le 0.5\text{ mEq/L/hour} ≤ 0.5 mEq/L/hour ).
High-Risk Ceiling: In patients with severe malnutrition, advanced liver disease, or baseline serum sodium < 115 mEq/L < 115\text{ mEq/L} < 115 mEq/L , limit correction to 6 to 8 mEq/L 6\text{ to } 8\text{ mEq/L} 6 to 8 mEq/L in 24 hours .
Emergency Rescue for Inadvertent Overcorrection: If serum sodium increases > 10 mEq/L > 10\text{ mEq/L} > 10 mEq/L within 24 hours, immediately stop hypertonic infusions, start an infusion of D 5 W D5W D 5 W ( 5 to 10 mL/kg/h 5\text{ to } 10\text{ mL/kg/h} 5 to 10 mL/kg/h ), and administer Desmopressin (DDAVP) ( 1 to 2 mcg 1\text{ to } 2\text{ mcg} 1 to 2 mcg IV or SC every 6–8 hours) to re-lower serum sodium and abort demyelination.
Sodium Disturbances: Hypernatremia
Hypernatremia is defined as a serum sodium concentration > 145 mEq/L > 145\text{ mEq/L} > 145 mEq/L , with severe hypernatremia > 160 mEq/L > 160\text{ mEq/L} > 160 mEq/L . In pediatrics, hypernatremia usually results from unreplaced free water losses (dehydration from viral gastroenteritis, osmotic diuresis, central or nephrogenic diabetes insipidus) or salt poisoning (improperly concentrated powdered infant formula, administration of hypertonic sodium bicarbonate).
Pathophysiology & Idiogenic Osmoles
During sustained hypertonicity, brain cells synthesize and accumulate idiogenic osmoles (organic intracellular solutes such as taurine, glycine, sorbitol, and myo-inositol) over 24 to 48 hours to preserve intracellular hydration and resist brain shrinkage. If free water is replaced too rapidly, extracellular osmolality plummets while idiogenic osmoles remain trapped intracellularly. Water rushes into brain cells along the steep osmotic gradient, provoking lethal cerebral edema, brain herniation, seizures, and death .
Controlled 48-Hour Rehydration Protocol
Restore Perfusion First: If the child presents in hypovolemic shock, immediately administer an isotonic crystalloid bolus ( 20 mL/kg 20\text{ mL/kg} 20 mL/kg of 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl ) over 15 to 30 minutes to restore intravascular volume before addressing the hypertonicity.
Calculate Free Water Deficit: Free Water Deficit (L) = Total Body Water (TBW) × ( Serum N a + 140 − 1 ) \text{Free Water Deficit (L)} = \text{Total Body Water (TBW)} \times \left( \frac{\text{Serum } Na^+}{140} - 1 \right) Free Water Deficit (L) = Total Body Water (TBW) × ( 140 Serum N a + − 1 ) (Where TBW = 0.6 × weight (kg) \text{TBW} = 0.6 \times \text{weight (kg)} TBW = 0.6 × weight (kg) in infants, or 0.5 × weight (kg) 0.5 \times \text{weight (kg)} 0.5 × weight (kg) in older children).
Safe Rate of Correction:
Infuse deficit plus maintenance fluids over 48 to 72 hours (at least 48 hours; extend to 72 hours if baseline N a + > 165 – 170 mEq/L Na^+ > 165\text{--}170\text{ mEq/L} N a + > 165 – 170 mEq/L ).
Target Rate: Decrease serum sodium at a rate ≤ 0.5 mEq/L/hour \le 0.5\text{ mEq/L/hour} ≤ 0.5 mEq/L/hour , and never exceed 10 to 12 mEq/L 10\text{ to } 12\text{ mEq/L} 10 to 12 mEq/L total reduction in any 24-hour window .
Solution: Typically 0.2 % to 0.45 % NaCl 0.2\%\text{ to } 0.45\%\text{ NaCl} 0.2% to 0.45% NaCl in 5 % dextrose 5\%\text{ dextrose} 5% dextrose . Monitor serum sodium every 2 to 4 hours to titrate infusion velocity.
Potassium Homeostasis & Disturbances
Potassium is the predominant intracellular cation ( 98 % 98\% 98% intracellular; normal serum concentration: 3.5 to 5.0 mEq/L 3.5\text{ to } 5.0\text{ mEq/L} 3.5 to 5.0 mEq/L in children, up to 5.5 to 6.0 mEq/L 5.5\text{ to } 6.0\text{ mEq/L} 5.5 to 6.0 mEq/L in preterm neonates). The resting membrane potential ( E m E_m E m ) of cardiac myocytes and excitable tissues is fundamentally determined by the intracellular-to-extracellular potassium ratio via the Nernst equation.
Hypokalemia ( < 3.5 mEq/L < 3.5\text{ mEq/L} < 3.5 mEq/L )
Etiology: Gastrointestinal losses (diarrhea, vomiting/nasogastric suction), renal wasting ( loop and thiazide diuretics, amphotericin B, cisplatin, aminoglycosides ), transcellular shifts (insulin administration, beta-2 adrenergic agonists, metabolic alkalosis), and hyperaldosteronism.
Electrocardiographic (ECG) Findings: Flattening or inversion of T waves, ST-segment depression, prominent U waves (appearing after the T wave), prolonged PR and QTc intervals, and ventricular arrhythmias (torsades de pointes).
Pharmacologic Replacement:
Oral Route (Preferred): Potassium chloride liquid or powder ( 1 to 2 mEq/kg/day 1\text{ to } 2\text{ mEq/kg/day} 1 to 2 mEq/kg/day divided q6–8h; maximum single dose 40 mEq 40\text{ mEq} 40 mEq ).
Intravenous Replacement: Required for severe symptoms, cardiac arrhythmias, or non-functioning GI tracts.
Peripheral IV Max Concentration: 40 mEq/L 40\text{ mEq/L} 40 mEq/L (higher concentrations cause severe chemical phlebitis and pain).
Central Line Max Concentration: 60 to 80 mEq/L 60\text{ to } 80\text{ mEq/L} 60 to 80 mEq/L (rarely up to 100 mEq/L 100\text{ mEq/L} 100 mEq/L in fluid-restricted intensive care settings).
Maximum Infusion Rate: Standard max rate is 0.25 to 0.5 mEq/kg/hour 0.25\text{ to } 0.5\text{ mEq/kg/hour} 0.25 to 0.5 mEq/kg/hour (not to exceed 10 to 20 mEq/hour 10\text{ to } 20\text{ mEq/hour} 10 to 20 mEq/hour in older children). Rates > 0.5 mEq/kg/h > 0.5\text{ mEq/kg/h} > 0.5 mEq/kg/h require mandatory continuous ECG telemetry .
The Magnesium Connection: Hypomagnesemia ( < 1.7 mg/dL < 1.7\text{ mg/dL} < 1.7 mg/dL ) causes refractory hypokalemia. Magnesium is an essential cofactor for the N a + / K + Na^+/K^+ N a + / K + ATPase; magnesium deficiency impairs intracellular potassium uptake and disinhibits renal outer medullary potassium (ROMK) channels, producing relentless urinary potassium wasting. Serum magnesium must be monitored and repleted (Magnesium sulfate 25 to 50 mg/kg 25\text{ to } 50\text{ mg/kg} 25 to 50 mg/kg IV over 30–60 min) to correct hypokalemia.
Hyperkalemia ( > 5.5 mEq/L > 5.5\text{ mEq/L} > 5.5 mEq/L ; Critical ≥ 6.5 mEq/L \ge 6.5\text{ mEq/L} ≥ 6.5 mEq/L )
Hyperkalemia is among the most lethal electrolyte emergencies encountered in pediatric critical care. As extracellular potassium rises, resting membrane potential depolarizes toward threshold, initially increasing myocardial excitability but subsequently causing sodium channel inactivation, conduction slowing, ventricular fibrillation, and asystole.
Etiology: Acute kidney injury, chronic renal failure, tumor lysis syndrome , crush injury/rhabdomyolysis, severe metabolic acidosis, adrenal crisis (salt-wasting CAH), and medications ( potassium-sparing diuretics, ACE inhibitors, ARBs, calcineurin inhibitors [tacrolimus, cyclosporine], trimethoprim, nonsteroidal anti-inflammatory drugs [NSAIDs] ).
Pseudohyperkalemia: Very common in pediatric practice! Caused by in vitro hemolysis during difficult heel sticks, traumatic venipunctures, prolonged tourniquet time, or extreme thrombocytosis/leukocytosis. Always verify unhemolyzed venous or arterial blood gas samples if clinical presentation and ECG do not correlate.
ECG Progression:
Tall, peaked, symmetric T waves with a narrow base (earliest sign).
Prolongation of the PR interval and flattening/loss of P waves.
Widening of the QRS complex and ST-segment depression.
Merging of the widened QRS with the T wave forming a sine-wave pattern (heralds imminent ventricular fibrillation or asystolic cardiac arrest). Three-Step Pharmacotherapy Sequence for Acute Severe Hyperkalemia:
- [Step 1: MEMBRANE STABILIZATION] ──► Immediately antagonizes cardiotoxicity; does NOT lower serum K+
- Calcium Gluconate 10%: 100 mg/kg IV over 5-10 min (Peripheral IV preferred)
- Calcium Chloride 10%: 20 mg/kg IV over 5-10 min (CENTRAL LINE ONLY)
- Onset: 1-3 minutes; Duration: 30-60 minutes
- │
- ▼
- [Step 2: INTRACELLULAR SHIFTING] ──► Rapidly drives potassium into cells; temporary bridge
- Regular Insulin (0.1 units/kg IV) + Dextrose (0.5-1 g/kg = D10W 5-10 mL/kg) over 30 min
- Inhaled Albuterol: 2.5-5 mg nebulized over 15 min
- Sodium Bicarbonate: 1-2 mEq/kg IV over 10-20 min (if concurrent metabolic acidosis)
- Onset: 15-30 minutes; Duration: 2-6 hours
- │
- ▼
- [Step 3: TOTAL-BODY ELIMINATION] ──► Permanently clears potassium from the body
- Loop Diuretics: Furosemide 1-2 mg/kg IV (if functional kidneys)
- Potassium Binders: Lokelma (SZC) 2.5-5 g PO; Patiromer; avoid SPS in neonates
- Hemodialysis / Continuous Renal Replacement Therapy (CRRT): Definitive removal
- Onset: 1-4 hours; Sustained removal
- Comprehensive Hyperkalemia Pharmacotherapy Table
- Mechanism & Medication Pediatric Dose Route Onset of Action Duration of Effect Clinical Pearls & Monitoring
- 1. Membrane Stabilization
Calcium Gluconate 10% 100 mg/kg 100\text{ mg/kg} 100 mg/kg ( 1.0 mL/kg 1.0\text{ mL/kg} 1.0 mL/kg , max 1 – 2 g 1\text{--}2\text{ g} 1 – 2 g ) IV over 5–10 min 1–3 minutes 30–60 minutes Preferred for peripheral IV access; contains 9.3 mg elemental Ca/mL 9.3\text{ mg elemental Ca/mL} 9.3 mg elemental Ca/mL . Repeat in 5–10 min if ECG changes persist.
Calcium Chloride 10% 20 mg/kg 20\text{ mg/kg} 20 mg/kg ( 0.2 mL/kg 0.2\text{ mL/kg} 0.2 mL/kg , max 1 g 1\text{ g} 1 g ) IV over 5–10 min 1–3 minutes 30–60 minutes CENTRAL LINE ONLY! Contains 27.2 mg elemental Ca/mL 27.2\text{ mg elemental Ca/mL} 27.2 mg elemental Ca/mL (3x more than gluconate). Severe extravasation necrosis if given peripherally.
2. Intracellular Shifting
Regular Insulin + Dextrose Regular Insulin 0.1 units/kg 0.1\text{ units/kg} 0.1 units/kg + + + Dextrose 0.5 – 1 g/kg 0.5\text{--}1\text{ g/kg} 0.5 – 1 g/kg ( D 10 W 5 – 10 mL/kg D10W\text{ } 5\text{--}10\text{ mL/kg} D 10 W 5 – 10 mL/kg ) IV over 30 min 15–30 minutes 2–6 hours Stimulates N a + / K + Na^+/K^+ N a + / K + ATPase. Check blood glucose at baseline, 15, 30, 60, and 120 minutes to prevent hypoglycemia.
Albuterol (Inhaled) 2.5 mg 2.5\text{ mg} 2.5 mg ( < 25 kg < 25\text{ kg} < 25 kg ); 5 mg 5\text{ mg} 5 mg ( ≥ 25 kg \ge 25\text{ kg} ≥ 25 kg ) or 0.15 mg/kg 0.15\text{ mg/kg} 0.15 mg/kg Nebulized over 15 min 20–30 minutes 2–4 hours Beta-2 agonist stimulates intracellular potassium uptake; additive with insulin. May cause tachycardia.
Sodium Bicarbonate 1 to 2 mEq/kg 1\text{ to } 2\text{ mEq/kg} 1 to 2 mEq/kg IV over 10–20 min 30–60 minutes 2–4 hours Indicated primarily when severe metabolic acidosis (pH < 7.15 < 7.15 < 7.15 ) coexists. Shifts K + K^+ K + via H + / K + H^+/K^+ H + / K + exchange.
3. Elimination
Furosemide 1 to 2 mg/kg 1\text{ to } 2\text{ mg/kg} 1 to 2 mg/kg IV 15–30 minutes 4–6 hours Inhibits N a + − K + − 2 C l − Na^+-K^+-2Cl^- N a + − K + − 2 C l − cotransporter in loop of Henle; requires functioning kidneys.
Sodium Zirconium Cyclosilicate (Lokelma) 2.5 to 5 g 2.5\text{ to } 5\text{ g} 2.5 to 5 g Oral suspension 1–2 hours 12–24 hours Inorganic crystalline cation exchanger selective for potassium; binds K + K^+ K + in exchange for N a + Na^+ N a + and H + H^+ H + throughout GI tract.
Sodium Polystyrene Sulfonate (SPS) 1 g/kg 1\text{ g/kg} 1 g/kg Oral or rectal 2–4 hours 6–12 hours CONTRAINDICATED in neonates, preterms, and postoperative bowel obstruction due to intestinal necrosis and colonic perforation.
Hemodialysis / CRRT Standard dialysis prescription Extracorporeal Immediate During run Most effective and definitive removal modality for refractory hyperkalemia in anuric acute kidney injury or tumor lysis syndrome.
Calcium Disturbances
Total serum calcium consists of three fractions: protein-bound (primarily to albumin, ∼ 40 % to 45 % \sim 40\%\text{ to } 45\% ∼ 40% to 45% ), complexed to anions (citrate, phosphate, bicarbonate, ∼ 10 % \sim 10\% ∼ 10% ), and ionized calcium ( C a 2 + Ca^{2+} C a 2 + , ∼ 50 % \sim 50\% ∼ 50% ) , which is the sole biologically active fraction regulating neuromuscular excitability and coagulation.
The Pitfall of Total and "Corrected" Calcium
Traditional clinical formulas attempt to estimate ionized calcium based on total calcium and serum albumin: Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ] \text{Corrected Calcium (mg/dL)} = \text{Measured Total Calcium (mg/dL)} + 0.8 \times [4.0 - \text{Serum Albumin (g/dL)}] Corrected Calcium (mg/dL) = Measured Total Calcium (mg/dL) + 0.8 × [ 4.0 − Serum Albumin (g/dL) ]
Important
BCPPS Board Rule: Corrected calcium formulas have been conclusively proven to be highly inaccurate and unreliable in critically ill pediatric patients and neonates . Acid-base disturbances profoundly alter calcium-albumin binding: alkalosis increases negative charges on albumin, driving binding of free calcium and acutely lowering ionized calcium (precipitating tetany despite a normal total calcium). Acidosis decreases binding, elevating ionized calcium. In pediatric intensive care and neonatal units, ionized calcium must always be measured directly (reference range: 1.15 to 1.35 mmol/L 1.15\text{ to } 1.35\text{ mmol/L} 1.15 to 1.35 mmol/L or 4.6 to 5.4 mg/dL 4.6\text{ to } 5.4\text{ mg/dL} 4.6 to 5.4 mg/dL ).
Hypocalcemia (Ionized C a 2 + < 1.1 mmol/L Ca^{2+} < 1.1\text{ mmol/L} C a 2 + < 1.1 mmol/L )
Clinical Manifestations: Neuromuscular irritability, jitteriness and tremors (neonates), laryngospasm, bronchospasm, tetany, carpopedal spasm, seizures, and prolonged QTc intervals on ECG. Signs include Chvostek sign (facial twitching on tapping facial nerve) and Trousseau sign (carpal spasm on inflating blood pressure cuff).
Emergency Treatment:
Calcium Gluconate 10%: 100 mg/kg 100\text{ mg/kg} 100 mg/kg ( 1 mL/kg 1\text{ mL/kg} 1 mL/kg , max 1 – 2 g 1\text{--}2\text{ g} 1 – 2 g ) IV infused slowly over 10 to 30 minutes under continuous cardiac telemetry.
Administration Warning: Rapid bolus administration can trigger severe bradycardia, sinus arrest, and hypotension . Stop infusion immediately if heart rate decreases by > 20 bpm > 20\text{ bpm} > 20 bpm . Extravasation of calcium solutions causes severe chemical cellulitis and tissue calcinosis.
Hypercalcemia (Total C a > 10.8 mg/dL Ca > 10.8\text{ mg/dL} C a > 10.8 mg/dL ; Ionized C a 2 + > 1.4 mmol/L Ca^{2+} > 1.4\text{ mmol/L} C a 2 + > 1.4 mmol/L )
Etiology: Malignancy, primary hyperparathyroidism, subcutaneous fat necrosis of the newborn (post-therapeutic hypothermia), vitamin D toxicity, Williams syndrome, and prolonged immobilization.
Treatment:
Volume Expansion: 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl at 1.5 to 2 × 1.5\text{ to } 2\times 1.5 to 2 × maintenance to promote renal calcium excretion.
Loop Diuretic: Furosemide 1 mg/kg 1\text{ mg/kg} 1 mg/kg IV once intravascular volume is fully repleted (prevents proximal and loop calcium reabsorption).
Calcitonin (Salmon): 4 to 8 units/kg 4\text{ to } 8\text{ units/kg} 4 to 8 units/kg SC or IM every 12 hours (rapid onset, but subject to tachyphylaxis within 48 hours).
Bisphosphonates: Zoledronic acid ( 0.02 to 0.05 mg/kg 0.02\text{ to } 0.05\text{ mg/kg} 0.02 to 0.05 mg/kg IV over 30 min) or Pamidronate ( 0.5 to 1.0 mg/kg 0.5\text{ to } 1.0\text{ mg/kg} 0.5 to 1.0 mg/kg IV over 4 hours) for sustained inhibition of osteoclastic bone resorption.
Practice Pearls & BCPPS Exam Traps
Exam Trap 1: Never administer Calcium Chloride via a peripheral IV catheter unless in active cardiac arrest with no other access. Its high osmolarity and ionized calcium concentration trigger catastrophic extravasation necrosis requiring plastic surgery debridement.
Exam Trap 2: Do not correct chronic hyponatremia faster than 8 to 10 mEq/L 8\text{ to } 10\text{ mEq/L} 8 to 10 mEq/L per 24 hours. If an exam question describes a child whose sodium rose by 16 mEq/L 16\text{ mEq/L} 16 mEq/L in 12 hours who then develops quadriparesis and dysarthria, identify Osmotic Demyelination Syndrome as the mechanism.
Board Rule: Always verify serum magnesium when evaluating refractory hypokalemia or refractory hypocalcemia; neither can be successfully normalized until hypomagnesemia is fully repleted.